1950

  • Fujirebio (formerly Fujizoki Pharmaceutical, Co., Inc.) is founded in Tokyo, Japan.

1966

  • Launch of HA Ag (TPHA), the world’s first hemagglutination test for syphilis.

1978

  • Launch of the syphilis SERODIA®-TP•PA test kit, destined to become a gold standard.

1981

  • Established Fujirebio Taiwan Inc.

1987

  • Established Fujirebio America, Inc. (merged to Fujirebio Diagnostics, Inc.) in USA.

1992

  • LUMIPULSE® 1200, the world’s first fully automated CLEIA testing instrument, is launched.

1995

  • INNOTEST® hTAU Ag is the world’s first commercialized biomarker kit for early detection of  Alzheimer’s disease.

1996

  • Launched LUMIPULSE f in Japan.

1998

  • Acquisition of Centocor Diagnostics of Pennsylvania, Inc. (USA, currently Fujirebio Diagnostics, Inc.), pioneer in oncology testing and developer of CA125II, CA19-9 and CA15-3.

2002

  • Launched ESPLINE® flu-A&B.

2005

  • Launched LUMIPULSE S and LUMIPULSE Presto II.

2006

  • Acquisition of CanAg Diagnostics AB (Sweden, currently Fujirebio Diagnostics AB), leader in oncology biomarker development.

2007

  • CL4800 is launched in Japan to support blood screening for Japan Red Cross (~2019).

2008

  • Acquisition of Advanced Life Science Institute, Inc.
  • Acquisition of American Biological Technologies, Inc. (merged to Fujirebio Diagnostics, Inc.).
  • LUMIPULSE  G1200, a mid-sized, cartridge-based instrument for fully automated CLEIA testing, is launched.

2010

  • Acquisition of Innogenetics N.V. (Belgium, currently Fujirebio Europe N.V.), world leader in specialty molecular and immunoassay testing.

2014

  • The LUMIPULSE G600II, a compact cartridge-based CLEIA benchtop analyzer, is launched.

2015

  • LUMIPULSE L2400, a high-volume instrument using bottle-type reagents is launched.

2017

  • Launched FUXION+ (Immunoassay and Clinical Chemistry platform).
  • Established Fujirebio Holdings, Inc., as parent company of Fujirebio Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe N.V. and other Fujirebio group companies.
  • Launched Lumipulse G β-Amyloid 1-42 and Lumipulse G Total Tau.

2018

  • Launched Lumipulse G β-Amyloid 1-40 and Lumipulse G pTau 181.

2019

  • Established Fujirebio Diagnostics Japan, Inc., focusing on OEM business in Japan.

2020

  • Launched ESPLINE SARS-CoV-2 and Lumipulse G SARS-CoV-2 Ag.
  • Established Fujirebio China Co., Ltd.